drugset
drugset / Trial / NCT04629729

FT819 in Subjects With B-cell Malignancies

NCT04629729 ↗

Phase 1 Active not recruiting 54 enrolled Fate Therapeutics
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Timeline

Start
2021-07-12
Primary completion
2025-06-18
Completion
2039-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject FT819 Cell therapy — —
Subject IL-2 Protein / enzyme biologic — —
Background Bendamustine Small molecule — —
Background Cyclophosphamide Other / unclassified — —
Background Fludarabine Small molecule — —

Indications

B-cell chronic lymphocytic leukemia precursor B-cell acute lymphoblastic leukemia